Clinical Trial Detail

NCT ID NCT02898116
Title A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Ludwig Institute for Cancer Research
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Ensartinib

Ensartinib

Age Groups: adult senior

Additional content available in CKB BOOST